Angela Mastronuzzi: Happy to share our multicenter retrospective study on a large cohort of GBM-LTS patients from nine Italian institutions
shared on LinkedIn:
“Happy to share our just published study!
“Clinicopathological and molecular landscape of 5-year IDH-wild-type glioblastoma survivors: A multicentric retrospective study”
Five-year glioblastoma (GBM) survivors are the minority of the isocitrate dehydrogenase (IDH)-wild-type GBM patients, and their molecular fingerprint is still largely unexplored.
Highlights:
• This is a multicenter retrospective study on a large cohort of GBM-LTS patients from nine Italian institutions.
• The mutational profile of pathogenic variants and CNV was similar in LTS and STS.
• LTS show no episignature but a global higher methylation in CpG islands.
• Methylation levels of distinct gene promoters correlated with prognosis.
Special thanks to the Italian Ministry of Health, Alleanza Contro il Cancro, AIRC – The Italian Foundation for Cancer Research ETS and Fondazione Umberto Veronesi ETS.”
Source: Angela Mastronuzzi/LinkedIn
Angela Mastronuzzi is pediatric hematologist-oncologist and the Head of Neuro-Oncology Unit at Bambino Gesù Children’s Hospital (Italy). She is also a professor at the UniCamillus International Medical University, and a Board Member of AIEOP (Associazione Italiana Ematologia Oncologia Pediatrica). Her main fields of interest are CNS tumors and innovative therapies. She is the author of more than 180 scientific publications in peer-reviewed international journals.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023